StockFin.ai
/
Sign inTry Free

Tools

Search Companies
News & Filings
Insights & Articles
FeaturesComing Soon
Pricing

Kabra Drugs Ltd (524322) — Board Meeting | 2 September 2026 (3 announcements)

· BSE 🟡 Notable Neutral
By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings
1Board Meeting🟡 Notable Neutral📄 PDF
📢 Key Event
Board approved FY2026 reports and AGM agenda
💡 Investor Takeaway
Shareholders will vote on key appointments and AGM matters in late September.

The board approved the Director's Report and Corporate Governance Report for FY2026, closed share transfer books from September 24-30, 2026, set September 23 as record date, launched e-voting from September 27-29, scheduled the AGM for September 30 in Chennai, reappointed Director Anand, appointed Karthik L & Associates as auditors, named Moonam Kapoor as director, and appointed Twinkle Agarwal as secretarial auditor; the meeting ran from 5:00 to 6:30 PM.

2Board Meeting🟡 Notable Neutral📄 PDF
📢 Key Event
Appointment of Mrs. Twinkle Agarwal as Secretarial Auditor
🔄 What Changed
Secretarial auditor appointed for FY 2026-2027 to 2027-2031
💡 Investor Takeaway
This ensures compliance with regulatory audit requirements for upcoming financial years.

Kabra Drugs Ltd appointed Mrs. Twinkle Agarwal as Secretarial Auditor for FY 2026-2027 to 2027-2031 following its September 2, 2026 board meeting, to comply with Companies Act 2013 and SEBI LODR requirements, as disclosed in Regulation 30 filings.

3Board Meeting🟡 Notable Neutral📄 PDF
📢 Key Event
Appointment of Karthik L & Associates as internal auditor
🔄 What Changed
New internal auditor appointed for FY 2026-27
💡 Investor Takeaway
This establishes formal internal audit oversight for the upcoming fiscal year.

Kabra Drugs Ltd appointed Karthik L & Associates as its internal auditor for FY 2026-27, effective September 2, 2026, to meet SEBI LODR compliance requirements. The appointment follows board approval and regulatory mandates under Companies Act 2013.

📊 Stock Analysis — 524322✨ Ask AI About This

About Kabra Drugs Ltd (524322)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹49.03 CrP/E: 6.5ROE: 25.6%ROCE: 30.1%

View full 524322 stock details →

📡 Get AI alerts when 524322 files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track 524322 — Free

💡 Ask AI about this filing

"When is the AGM voting deadline?""What is the impact of auditor change on financials?""How does director reappointment affect governance?"
Ask AI Free →

📊 More 524322 filings

See all 524322 filings →

🔥 Also filed on 2 September 2026

WAAREEENERWaaree Energies LtdAnnual ReportPEARLPOLYPearl Polymers LtdAnnual Report544627Purple Wave Infocom LtdAnnual Report544437Marc Loire Fashions LtdAnnual ReportRTNINDIARattanIndia Enterprises LtdAnnual Report544596Safecure Services LtdAnnual Report
View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day